Novo’s latest trial setback strengthens Lilly’s advantage in weight-loss market
Novo Nordisk’s disclosure of late-stage results for its CagriSema obesity drug has amplified concerns about the Danish drugmaker’s competitiveness against Eli Lilly. CagriSema produced a 23% average body-weight reduction at 84 weeks versus 25.5% for Lilly’s tirzepatide in the trial, prompting a sharp sell-off in Novo shares and buoying Lilly’s stoc…